Saturday, September 7, 2024
9/7/2024
ABSTRACT Variants in the ABCA4 gene are a fundamental cause of several inherited retinal degenerations (IRDs), including Stargardt macular dystrophy, fundus flavimaculatus, and cone-rod dystrophy; these three ABCA4- driven diseases cause blindness in 1.4 million people worldwide. As a result, genetic testing of ABCA4 is increasingly common in clinical settings. Of the 1,485 identified missense variants in ABCA4, 50% are of unknown pathogenicity (variants of unknown significance, VUS). This genetic uncertainty leads to three key problems: (i) for IRD patients who have multiple unclassified ABCA4 mutations, it is impossible to predict which variant will cause disease in relatives who have not yet developed the disease; (ii) development of variant-specific therapies will remain limited; and (iii) these variants cannot be used to predict disease prospectively, which facilitates important life-planning decisions for patients and which is critical to direct patients to new clinical trials. Our proposed study aims to unravel the clinical significance of ABCA4 genetic variants of unknown significance (VUS) using in silico and in vitro functional analyses in combination. In this proposal, we have assembled a team of investigators with extensive expertise in complementary fields: protein biochemistry, computational biology, bioimaging, and biostatistics to create a “sequence-structure-function” workflow, whereby in silico 3D protein structural analysis of ABCA4 sequence variants will be used as a tool to predict disease severity/clinical pathogenicity in combination with high throughput functional analysis. The combined expertise of the investigators and our unique biochemical resources allow us to carry out this project. Successful completion of this study will be a significant and critical step forward in understanding the biology of ABCA4-mediated IRDs and the characterization of variants for pathogenicity risk prediction. The proposal incorporates interrelated initiatives focused on DEIA (Diversity, Equity, Inclusion, and Accessibility), which will include training opportunities for students at different stages of their careers, interdisciplinary research training, fostering inclusive and collaborative team science, and engaging with community stakeholders to raise awareness and generate interest in vision research. Together, these efforts will contribute to the creation of a transformative framework that promotes diversity within the biomedical research community while aligning with our scientific objectives.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).
